Clinical Trial Update: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 clinical trial evaluating nilotinib in chronic myeloid leukemia patients with suboptimal response, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase | Phase 4 | Status: COMPLETED | Results posted: 2015-02-09